Vascular Biogenics Ltd (VBLT)

[gr8db8]

This is an interesting list. 3 on the list were phase III. 3 were angiogenic inhibitors. This is why avastin, even though it sucks, is the SOC. Many have tried but none have been able to beat avastin as the SOC.

Still, VB-111 looks promising and I'm looking forward to the interim in Sept/Oct.

http://www.sciencedirect.com/science/article/pii/S111003621630036X

Table 3. Summarizes different agents used for the treatment of rGBM alone or in combination failed to achieve significant response in phase I/II/III trials.

Drug/Phase Type of drug

Verubulin/Phase II Microtubule destabilizer and Vascular disrupting agent
Erlotinib + temsirolimus/PhaseII Epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin (mTOR)
Sunitinib/Phase II Inhibitor of several receptor tyrosine kinases
Fotemustine/Phase I; Phase II VEGF inhibitor with Nitrosurea
Enzastaurin/Phase II, Phase III Selective oral inhibitor of protein kinase Cß
Cediranib/Phase III [monotherapy or in combination with Lomustine] Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor
Dasatinib/Phase II Multitargeted tyrosine kinase inhibitor
Bosutinib/Phase II Kinase inhibitor of Src and Abl
Cilengitide/Phase II av integrin antagonist
CT-322/Phase II Inhibitor of VEGFR-2
Veliparib/Phase I PARP inhibitor
Pazopanib + Lapatinib/Phase II Antiangiogenic pazopanib; ErbB inhibitor lapatinib
Gimatecan/Phase II Lipophilic oral camptothecin analog
Nintedanib/Phase II Triple angiokinase inhibitor
Vandetanib/Phase II Multi targeted tyrosine kinase inhibitor
Patupilone/Phase II Natural microtubule-stabilizing cytotoxic agent
Vorinostat/Phase II; Romidepsin/Phase II Histone deacetylase (HDAC) inhibitor
TLN-4601/Phase II Ras-MAPK signaling pathway inhibitor
Aflibercept/Phase II VEGF Trap
Sagopilone/Phase II Lipophylic and synthetic analog of epothilone B
Rilotumumab/Phase II A fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF)
Imatinib + hydroxyurea/Phase II Protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase
Didemnin B/Phase II Natural product derived from the Caribbean Tunic inhibit all phases of the cell cycle
Induces rapid and wholesale apoptosis through dual inhibition of PPT1 and EEF1A1
KRN8602(MX2)/Phase II A novel morpholino anthracycline with capacity to cross BBB
Thalidomide/Phase II Putative inhibitor of angiogenesis
Paclitaxel/Phase II Enhances the polymerization of tubulin to stable microtubules
Cystemustine/Phase II Nitrosourea
Marimastat/Phase II Matrix metalloproteinase inhibitor
XR5000/Phase II Tricyclic carboxamide that intercalates DNA and inhibits both topoisomerase I and II
Gefitinib/Phase II; Erlotinib/Phase II Epidermal growth factor receptor tyrosine kinase inhibitor
Cloretazine/Phase II Novel alkylating agent belonging to 1,2-bis(sulfonyl)hydrazines class
Cetuximab/Phase II Anti EGFR monoclonal Antibody
Trabedersen/Phase II TGF-ß2 inhibitor
Bortezomib/Phase II Proteasome inhibitor
Convection-enhanced delivery (CED) of cintredekin besudotox (CB) was compared with Gliadel wafers (GW)/Phase III Nitrosurea in Wafer